Article
The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer.
Journal of cancer research and clinical oncology - 1 May 2014
Zhao Jingya, Wang Xiaoying, Xue Liang, Xu Nuo, Ye Xin, Zeng Haiying, Lu Shaohua, Huang Jie, Akesu Sujie, Xu Chen, He Deming, Tan Yunshan, Hong Qunying, Wang Qun, Zhu Guanshan, Hou Yingyong, Zhang Xin
Abstract excerpt
PURPOSE: We aimed to quantify the epidermal growth factor receptor (EGFR) mutation in tumors and to analyze its prediction of EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment efficacy in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients. METHODS: We examined EGFR mutation status in 124 lung cancer samples by direct sequencing and amplification refractory mutation system. Among them, 41 were...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antibodies
- Carcinoma, Non-Small-Cell Lung
- Disease-Free Survival
- ErbB Receptors
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Male
- Middle Aged
- Mutation